These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 1773137)
1. A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia. Gallacher SJ; Ralston SH; Fraser WD; Dryburgh FJ; Cowan RA; Logue FC; Boyle IT Bone Miner; 1991 Dec; 15(3):249-56. PubMed ID: 1773137 [TBL] [Abstract][Full Text] [Related]
2. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy. Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351 [TBL] [Abstract][Full Text] [Related]
3. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate. Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202 [TBL] [Abstract][Full Text] [Related]
4. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762 [TBL] [Abstract][Full Text] [Related]
5. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Walls J; Ratcliffe WA; Howell A; Bundred NJ Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531 [TBL] [Abstract][Full Text] [Related]
6. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Body JJ; Dumon JC Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034 [TBL] [Abstract][Full Text] [Related]
7. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Wimalawansa SJ Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347 [TBL] [Abstract][Full Text] [Related]
8. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Sawyer N; Newstead C; Drummond A; Cunningham J Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615 [TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Gurney H; Grill V; Martin TJ Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988 [TBL] [Abstract][Full Text] [Related]
10. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Ralston SH; Alzaid AA; Gardner MD; Boyle IT Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513 [TBL] [Abstract][Full Text] [Related]
11. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Davis JR; Heath DA Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920 [TBL] [Abstract][Full Text] [Related]
13. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417 [TBL] [Abstract][Full Text] [Related]
14. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597 [TBL] [Abstract][Full Text] [Related]
15. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Davenport A; Goel S; Mackenzie JC Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916 [TBL] [Abstract][Full Text] [Related]
16. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925 [TBL] [Abstract][Full Text] [Related]
17. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484 [TBL] [Abstract][Full Text] [Related]
18. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922 [TBL] [Abstract][Full Text] [Related]
19. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Gurney H; Kefford R; Stuart-Harris R Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054 [TBL] [Abstract][Full Text] [Related]